JPRN-jRCT2031260234 Cancer (Breakthru Medicin) Microsatellite instability-high colorectal cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines JPRN-jRCT2031260234 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 21 July 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why JPRN-jRCT2031260234 is a hot trial to watch
Microsatellite instability-high colorectal cancer is being segmented by mechanism, treatment setting, geography and endpoint architecture. JPRN-jRCT2031260234 is notable because it evaluates Cancer (Breakthru Medicin) in a Phase 3 design sponsored by Astellas Pharma Global Development, Inc.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | JPRN-jRCT2031260234 |
| Official title | A Phase 3, Global, Multi-center, Double-blind, Randomized Study of ASP2138 plus Chemotherapy (CAPOX or mFOLFOX6) with Pembrolizumab vs Placebo plus Chemotherapy with or without Pembrolizumab in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma in Participants Whose Tumors Are HER2-negative and Claudin (CLDN) 18.2-positive |
| Phase / status | Phase 3 / 募集前 |
| Intervention | Cancer (Breakthru Medicin) |
| Sponsor | Astellas Pharma Global Development, Inc. |
| Geography | United States, Japan |
| Enrollment | 570 |
| Primary endpoint | - 全生存期間（OS）（ランダム化日から死因を問わない死亡が記録される日までの期間と定義する） - 無増悪生存期間（PFS）（ランダム化日から、RECIST V1.1に基づく盲検下独立中央判定（BICR）による画像上の病勢進行日、又は死因を問わない死亡日のいずれか早い方までの期間と定義する） |
| Endpoint time frame | Not reported |
| Primary completion / readout proxy | 2031-02-28 |
Protocol design and endpoint interpretation
The indexed record describes a Phase 3 study of Cancer (Breakthru Medicin) in Microsatellite instability-high colorectal cancer.
Allocation is Randomized, masking is Double, and the intervention model is Parallel Assignment. Planned enrollment of 570 participants across United States, Japan shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- - 全生存期間（OS）（ランダム化日から死因を問わない死亡が記録される日までの期間と定義する） - 無増悪生存期間（PFS）（ランダム化日から、RECIST V1.1に基づく盲検下独立中央判定（BICR）による画像上の病勢進行日、又は死因を問わない死亡日のいずれか早い方までの期間と定義する） (time frame not reported)
- - Overall survival (OS), defined as the time from the date of randomization until the documented date of death from any cause - Progression-free survival (PFS), defined as the time from the date of randomization until the date of radiographic disease progression (per RECIST V1.1 by blinded independent central review [BICR]) or death from any cause, whichever is earlier (time frame not reported)
Readout outlook and evidence gap
The current protocol points to 2031-02-28 as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Trial-sourced asset: Cancer (Breakthru Medicin). The Drug & Asset MCP enrichment step is designed to add normalized targets, modality and global development status when an exact asset match is available.
Trial-sourced sponsor: Astellas Pharma Global Development, Inc.. Company & Deal Intelligence MCP is the companion workflow for resolving organization identity, corporate profile and partnering context.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
JPRN-jRCT2031260234 provides a focused lens on Microsatellite instability-high colorectal cancer development. Its value will be determined by whether Cancer (Breakthru Medicin) can convert the current Phase 3 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
